Bessemer Venture Partners is positioning itself against the private equity tide in India's healthcare sector by focusing on single-speciality chains rather than multi-speciality hospitals. According to reports from Mint, the US-based venture capital firm estimates that the organized single-speciality segment will grow to $12.3 billion by 2030 from $4.4 billion in 2025, implying a 22% compounded annual growth rate—more than twice the pace expected for multi-speciality hospital chains. Nithin Kaimal, partner at Bessemer Venture Partners, explained that category leaders in single-speciality care will acquire smaller clinics to broaden their footprint, while multi-speciality hospitals face pressure to improve productivity after a decade of aggressive expansion.
The healthcare sector has shown significant improvement in operational efficiency over the past decade. As reported by Mint, Bessemer estimates that average revenue per operating bed rose from $241 in 2015 to $625 in 2025, while average length of stay fell from 5.1 days to 3.8 days. The firm's investment thesis indicates that setting up a single-speciality centre can require $0.1 million for a dental clinic to $4.2 million for an oncology centre, with annual revenue potential at maturity spanning $0.1 million for dental to $7.1 million for oncology. Kaimal noted that the ability to maximize average revenue per operating bed and optimize average length of stay becomes super important for multi-speciality hospitals.
Bessemer has made significant investments in single-speciality healthcare platforms, including $24 million in NephroPlus (dialysis) in 2021, $13.8 million in Pluro (IVF) in 2025, and $31 million in Sukino (continuum care) in January. According to Mint, the firm is investing out of a dedicated India vehicle announced in 2021 and recently closed $350 million for its second India fund. Industry estimates cited in Bessemer's investment thesis deck put cumulative PE investment in offline healthcare providers at $10.6 billion between 2015 and 2025, with notable deals including Blackstone Group's $591.1 million investment in Quality Care and Baring Private Equity Asia's $656 million purchase of a majority stake in Indira IVF.
Despite the growth potential, experts caution about the challenges of scaling healthcare businesses. Saurabh Singhavi, director and chief operating officer at Alsisar Impact Pvt. Ltd, highlighted that quality and trust remain the biggest risks, especially for doctor-led brands that can prove fragile in a downturn. As reported by Mint, he emphasized that such businesses are built largely on outcomes and word of mouth rather than customer-acquisition playbooks common in consumer internet. Dr Arindam Basu from A Square Capital argued that Bessemer's single-speciality roadmap risks being too singular and linear for a sector where models routinely evolve to survive, noting that India's first wave of speciality hospitals often broadened into multi-speciality formats to capture larger markets.
